279 related articles for article (PubMed ID: 31717342)
1. Structural Implications of STAT3 and STAT5 SH2 Domain Mutations.
de Araujo ED; Orlova A; Neubauer HA; Bajusz D; Seo HS; Dhe-Paganon S; Keserű GM; Moriggl R; Gunning PT
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31717342
[TBL] [Abstract][Full Text] [Related]
2. Direct Targeting Options for STAT3 and STAT5 in Cancer.
Orlova A; Wagner C; de Araujo ED; Bajusz D; Neubauer HA; Herling M; Gunning PT; Keserű GM; Moriggl R
Cancers (Basel); 2019 Dec; 11(12):. PubMed ID: 31817042
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription (STAT)5 activation by BCR/ABL is dependent on intact Src homology (SH)3 and SH2 domains of BCR/ABL and is required for leukemogenesis.
Nieborowska-Skorska M; Wasik MA; Slupianek A; Salomoni P; Kitamura T; Calabretta B; Skorski T
J Exp Med; 1999 Apr; 189(8):1229-42. PubMed ID: 10209040
[TBL] [Abstract][Full Text] [Related]
4. Somatic STAT3 mutations in large granular lymphocytic leukemia.
Koskela HL; Eldfors S; Ellonen P; van Adrichem AJ; Kuusanmäki H; Andersson EI; Lagström S; Clemente MJ; Olson T; Jalkanen SE; Majumder MM; Almusa H; Edgren H; Lepistö M; Mattila P; Guinta K; Koistinen P; Kuittinen T; Penttinen K; Parsons A; Knowles J; Saarela J; Wennerberg K; Kallioniemi O; Porkka K; Loughran TP; Heckman CA; Maciejewski JP; Mustjoki S
N Engl J Med; 2012 May; 366(20):1905-13. PubMed ID: 22591296
[TBL] [Abstract][Full Text] [Related]
5. Novel multiplexed assay for identifying SH2 domain antagonists of STAT family proteins.
Takakuma K; Ogo N; Uehara Y; Takahashi S; Miyoshi N; Asai A
PLoS One; 2013; 8(8):e71646. PubMed ID: 23977103
[TBL] [Abstract][Full Text] [Related]
6. A common epitope is shared by activated signal transducer and activator of transcription-5 (STAT5) and the phosphorylated erythropoietin receptor: implications for the docking model of STAT activation.
Barber DL; Beattie BK; Mason JM; Nguyen MH; Yoakim M; Neel BG; D'Andrea AD; Frank DA
Blood; 2001 Apr; 97(8):2230-7. PubMed ID: 11290583
[TBL] [Abstract][Full Text] [Related]
7. Severe growth deficiency is associated with STAT5b mutations that disrupt protein folding and activity.
Varco-Merth B; Feigerlová E; Shinde U; Rosenfeld RG; Hwa V; Rotwein P
Mol Endocrinol; 2013 Jan; 27(1):150-61. PubMed ID: 23160480
[TBL] [Abstract][Full Text] [Related]
8. Allosteric Communication across STAT3 Domains Associated with STAT3 Function and Disease-Causing Mutation.
Namanja AT; Wang J; Buettner R; Colson L; Chen Y
J Mol Biol; 2016 Feb; 428(3):579-589. PubMed ID: 26774853
[TBL] [Abstract][Full Text] [Related]
9. Allosteric regulation in STAT3 interdomains is mediated by a rigid core: SH2 domain regulation by CCD in D170A variant.
Zhao T; Karki N; Zoltowski BD; Matthews DA
PLoS Comput Biol; 2022 Dec; 18(12):e1010794. PubMed ID: 36542668
[TBL] [Abstract][Full Text] [Related]
10. An invertebrate signal transducer and activator of transcription 5 (STAT5) ortholog from the disk abalone, Haliotis discus discus: Genomic structure, early developmental expression, and immune responses to bacterial and viral stresses.
Bathige SD; Umasuthan N; Park HC; Lee J
Dev Comp Immunol; 2016 Mar; 56():46-56. PubMed ID: 26616564
[TBL] [Abstract][Full Text] [Related]
11. Changes in signal transducer and activator of transcription 3 (STAT3) dynamics induced by complexation with pharmacological inhibitors of Src homology 2 (SH2) domain dimerization.
Resetca D; Haftchenary S; Gunning PT; Wilson DJ
J Biol Chem; 2014 Nov; 289(47):32538-47. PubMed ID: 25288792
[TBL] [Abstract][Full Text] [Related]
12. Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced T(H)17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome.
Renner ED; Rylaarsdam S; Anover-Sombke S; Rack AL; Reichenbach J; Carey JC; Zhu Q; Jansson AF; Barboza J; Schimke LF; Leppert MF; Getz MM; Seger RA; Hill HR; Belohradsky BH; Torgerson TR; Ochs HD
J Allergy Clin Immunol; 2008 Jul; 122(1):181-7. PubMed ID: 18602572
[TBL] [Abstract][Full Text] [Related]
13. Exploring dual inhibitors for STAT1 and STAT5 receptors utilizing virtual screening and dynamics simulation validation.
Raj U; Kumar H; Gupta S; Varadwaj PK
J Biomol Struct Dyn; 2016 Oct; 34(10):2115-29. PubMed ID: 26471877
[TBL] [Abstract][Full Text] [Related]
14. Consequences of the disease-related L78R mutation for dimerization and activity of STAT3.
Domoszlai T; Martincuks A; Fahrenkamp D; Schmitz-Van de Leur H; Küster A; Müller-Newen G
J Cell Sci; 2014 May; 127(Pt 9):1899-910. PubMed ID: 24569879
[TBL] [Abstract][Full Text] [Related]
15. Jak2-Stat5 interactions analyzed in yeast.
Barahmand-Pour F; Meinke A; Groner B; Decker T
J Biol Chem; 1998 May; 273(20):12567-75. PubMed ID: 9575217
[TBL] [Abstract][Full Text] [Related]
16. Somatic
Savola P; Brück O; Olson T; Kelkka T; Kauppi MJ; Kovanen PE; Kytölä S; Sokka-Isler T; Loughran TP; Leirisalo-Repo M; Mustjoki S
Haematologica; 2018 Feb; 103(2):304-312. PubMed ID: 29217783
[TBL] [Abstract][Full Text] [Related]
17. Identification of the linker-SH2 domain of STAT as the origin of the SH2 domain using two-dimensional structural alignment.
Gao Q; Hua J; Kimura R; Headd JJ; Fu XY; Chin YE
Mol Cell Proteomics; 2004 Jul; 3(7):704-14. PubMed ID: 15073273
[TBL] [Abstract][Full Text] [Related]
18. Physician Education: The Erythropoietin Receptor and Signal Transduction.
Yoshimura A; Arai K
Oncologist; 1996; 1(5):337-339. PubMed ID: 10388012
[TBL] [Abstract][Full Text] [Related]
19. A cell-permeable Stat3 SH2 domain mimetic inhibits Stat3 activation and induces antitumor cell effects in vitro.
Zhao W; Jaganathan S; Turkson J
J Biol Chem; 2010 Nov; 285(46):35855-65. PubMed ID: 20807764
[TBL] [Abstract][Full Text] [Related]
20. In silico simulations of STAT1 and STAT3 inhibitors predict SH2 domain cross-binding specificity.
Szelag M; Sikorski K; Czerwoniec A; Szatkowska K; Wesoly J; Bluyssen HA
Eur J Pharmacol; 2013 Nov; 720(1-3):38-48. PubMed ID: 24211327
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
